John Hartner, CEO of Dimension Inx, sees smoother regulatory pathways as essential to the near term availability of surgically friendly tissue for grafts.
“ARMI can assist all the members in the regenerative medicine ecosystem with assistance in the regulatory area. With our ARMI/BioFabUSA Membership we hope to partner with others to focus on bringing these innovations to market for better patient outcomes,” Hartner commented.
Dimension Inx was co-founded by Dr. Ramille N. Shah, professor of Materials Science and Engineering and of Surgery at Northwestern University in Chicago, IL USA, and Dr. Adam E. Jakus, an alumnus of Prof. Shah's Tissue Engineering and Additive Manufacturing (TEAM) Laboratory in August of 2017.
With the addition of John Hartner as CEO, the Dimension Inx team brings together scientific, engineering, manufacturing, clinical, and business expertise to propel Dimension Inx to the forefront of advanced material, medical, and manufacturing industries where the company seeks to transform the landscape of regenerative medicine manufacturing, improving the lives of medical patients, and enabling the creation and industrialization of new, advanced high technologies.
“We created our 3D printable biomaterial platforms to allow for both the wider scaling of the biofabrication industry, and for better patient outcomes while keeping the surgeons and physicians in mind,” continued Hartner.
With its highly innovative, versatile, and scalable 3D printable biomaterial platform technologies, Dimension Inx, headquartered in Chicago, IL, wants to move the biomedical industry forward from lab-scale research to large-scale hard and soft tissue and organ biofabrication.
The company is making significant scientific breakthroughs with its 3D-Painting platform technology, which encompasses many new, highly innovative, non-biomaterials and surgically friendly biomaterials, including Hyperelastic Bone™ for orthopedic and craniomaxillofacial indications, 3D-Graphene & 3D-Graphite for cardiac, neuro, and muscular applications, organ specific “Tissue Papers” for targeted soft tissue and organ repair, and more. These innovations could contribute to transformations in clinical practice once they are translated into medical products at commercial scale.
In joining ARMI, Dimension Inx will be contributing its extensive biomaterial development and fabrication expertise, supporting national efforts to help scale the biofabrication industry, as well as accelerate the adoption and regulatory approval of Dimension Inx’s innovative biomaterials and products.